-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCLETIS ANNOUNCES FIRST PARTICIPANT DOSED IN A GLOBAL PHASE III CLINICAL PROGRAM OF ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST ASC30 FOR CHRONIC WEIGHT MANAGEMENT

Reuters·08/30/2026 10:15:03

Please log in to view news